Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1
Disclosed is a method for predicting the risk of developing renal failure or mortality for a subject suffering from diabetes mellitus. More specifically, a method is disclosed for predicting the risk of developing renal failure for a subject suffering from diabetes mellitus, the method including the steps of determining the amounts of PLGF and sFlt-1 in a sample of a subject suffering from diabetes mellitus and comparing the amounts of PLGF and sFlt-1 determined with reference amounts of PLGF and sFlt-1, whereby the risk of developing renal failure is predicted. Also disclosed are diagnostic devices and kits for carrying out the aforementioned methods.
1. A method for predicting a risk of developing chronic renal insufficiency in a subject suffering from diabetes mellitus type I, the method comprising:
(a) contacting a sample from the subjects with a ligand specific for placental growth factor (PLGF);
(b) calculating an amount of PLGF in the sample based contacting step (a);
(c) contacting a sample from the subject with a ligand specific for soluble Flt-1 (sFlt-1);
(d) calculating an amount of sFlt-1 in the sample based contacting of step (c)
comparing the calculated amount of PLGF and the calculated amount of sFlt-1 with a reference amount of PLGF and a reference amount of sFlt-1, respectively; and
predicting a risk of developing chronic renal insufficiency if the calculated amount of PLGF is greater than a reference amount of PLGF between 12 and 15 pg/ml and the calculated amount of sFlt-1 is greater than a reference amount of sFlt-1 between 90 and 120 pg/ml.
2. The method of claim 1 , wherein the reference amount of PLGF is 13 pg/ml and the reference amount of sFlt-1 is 95 pg/ml.
3. A method for determining susceptibility of a subject to a renal therapy wherein the subject suffers from diabetes mellitus type I, the method comprising:
(a) contacting a sample from the subject with a ligand specific for placental growth factor (PLGF)
(b) calculating an amount of PLGF in the sample based on contacting step (a);
(c) contacting a sample from the subject with a ligand specific for soluble Flt-1 (sFlt-1);
(d) calculating an amount of sFlt-1 in the sample based on contacting step (c); and
assessing the subject as susceptible to renal therapy if
the calculated amount of PLGF is greater than a reference amount of PLGF between 12 and 15 pg/ml and the calculated amount of sFlt-1 is greater than a reference amount of sFlt-1 between 90 and 120 pg/ml.
4. The method of claim 3 , wherein the reference amount of PLGF is 13 pg/ml and the reference amount of sFlt-1 is 95 pg/ml.
5. The method of claim 3 , wherein the renal therapy is selected from the group consisting of blood pressure lowering drugs, aspirin, statins, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers.
6. A method for predicting a risk of mortality in a subject suffering from diabetes mellitus type I, the method comprising:
(a) contacting a sample from the subject with a ligand specific for placental growth factor (PLGF);
(b) calculating an amount of PLGF in the sample based on contacting step (a);
(c) contacting a sample from the subject with a ligand specific for soluble Flt-1 (sFlt-1);
(d) calculating an amount of sFlt-1 in the sample based on contacting step (c); and
predicting an increased risk of mortality if the calculated amount of PLGF is greater than a reference amount of PLGF between 12 and 15 pg/ml and the calculated amount of sFlt-1 is greater than a reference amount of sFlt-1 between 90 and 120 pg/ml.
7. The method of claim 6 , wherein the reference amount of PLGF is 13 pg/ml and the reference amount of sFlt-1 is 95 pg/ml.
8. The method according to claim 1 wherein the subject suffering from diabetes mellitus type I is apparently healthy with respect to kidney function.
9. The method according to claim 3 wherein the subject suffering from diabetes mellitus type I is apparently healthy with respect to kidney function.
10. The method according to claim 6 wherein the subject suffering from diabetes mellitus type I is apparently healthy with respect to kidney function.
11. The method according to claim 1 wherein predicting a risk of developing chronic renal insufficiency comprises a predictive window of at least 12 years.
12. The method according to claim 6 wherein predicting a risk of mortality comprises a predictive window of at least 12 years.
13. A method for managing treatment of a patient determining susceptibility suffering from diabetes mellitus type I, the method comprising:
determining susceptibility of the patient for a renal therapy by
(a) contacting a sample from the subject with a ligand specific for placental growth factor (PLGF),
(b) calculating an amount of PLGF in the sample based on contacting step (a),
(c) contacting a sample from the subject with a ligand specific for soluble Flt-1 (sFlt-1),
(d) calculating an amount of sFlt-1 in the sample based on contacting step (c),
assessing the subject as susceptible to renal therapy if the calculated amount of PLGF is greater than a reference amount of PLGF between 12 and 15 pg/ml and the calculated amount of sFlt-1 is greater than a reference amount of sFlt-1between 90 and 120 pg/ml; and
initiating a treatment for renal insufficiency if the patient is susceptible to renal therapy, wherein the treatment comprises administration of blood pressure lowering drugs, aspirin, statins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers or combinations thereof.